86 related articles for article (PubMed ID: 38807)
1. [Course of psychopathologic and extrapyramidal motor symptoms during long-term treatment of schizophrenic patients with psycholeptic drugs (author's transl)].
Schilkrut R; Duran E; Haverbeck C; Katz I; Vidal P
Arzneimittelforschung; 1978; 28(9):1494-5. PubMed ID: 38807
[TBL] [Abstract][Full Text] [Related]
2. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia.
Chakos MH; Mayerhoff DI; Loebel AD; Alvir JM; Lieberman JA
Psychopharmacol Bull; 1992; 28(1):81-6. PubMed ID: 1609046
[TBL] [Abstract][Full Text] [Related]
3. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
Chouinard G; Annable L; Ross-Chouinard A
Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
[No Abstract] [Full Text] [Related]
4. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
5. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
Altamura AC; Mauri MC; Girardi T; Panetta B
Int J Clin Pharmacol Res; 1990; 10(4):223-8. PubMed ID: 2079381
[TBL] [Abstract][Full Text] [Related]
6. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Chouinard G; Annable L; Campbell W
J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
[TBL] [Abstract][Full Text] [Related]
7. First-episode schizophrenia: the importance of early intervention and subjective tolerability.
Kasper S
J Clin Psychiatry; 1999; 60 Suppl 23():5-9. PubMed ID: 10625193
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic-withdrawal akathisia versus antipsychotic-induced akathisia: further evidence for the existence of tardive akathisia.
Dufresne RL; Wagner RL
J Clin Psychiatry; 1988 Nov; 49(11):435-8. PubMed ID: 2903141
[TBL] [Abstract][Full Text] [Related]
9. The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment.
Gerlach J
J Clin Psychiatry; 1999; 60 Suppl 23():20-4. PubMed ID: 10625196
[TBL] [Abstract][Full Text] [Related]
10. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
Weiden PJ; Cutler AJ; Polymeropoulos MH; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S12-9. PubMed ID: 18334908
[TBL] [Abstract][Full Text] [Related]
11. [Non-extrapyramidal motor side-effects in long-term therapy with neuroleptics: an analysis of 99 patients].
Ginzel I; Hilger E; Barnas C
Wien Klin Wochenschr; 2002 Jan; 114(1-2):38-43. PubMed ID: 12407934
[TBL] [Abstract][Full Text] [Related]
12. [Follow-up treatment of schizophrenic psychoses: advantages and disadvantages of long-term medication].
Steuber H; Kind J; Lohrengel S; Müller P
Arzneimittelforschung; 1978; 28(9):1492-3. PubMed ID: 38806
[TBL] [Abstract][Full Text] [Related]
13. A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia.
Perez V; Cañas F; Tafalla M;
Int Clin Psychopharmacol; 2008 May; 23(3):138-49. PubMed ID: 18408528
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.
Emsley R; Berwaerts J; Eerdekens M; Kramer M; Lane R; Lim P; Hough D; Palumbo J
Int Clin Psychopharmacol; 2008 Nov; 23(6):343-56. PubMed ID: 18854723
[TBL] [Abstract][Full Text] [Related]
15. Short and long term effects of antipsychotic medication on smooth pursuit eye tracking in schizophrenia.
Hutton SB; Crawford TJ; Gibbins H; Cuthbert I; Barnes TR; Kennard C; Joyce EM
Psychopharmacology (Berl); 2001 Sep; 157(3):284-91. PubMed ID: 11605084
[TBL] [Abstract][Full Text] [Related]
16. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia.
Kaiser R; Tremblay PB; Klufmöller F; Roots I; Brockmöller J
Mol Psychiatry; 2002; 7(7):695-705. PubMed ID: 12192613
[TBL] [Abstract][Full Text] [Related]
17. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.
Johnson DA
J Clin Psychiatry; 1984 May; 45(5 Pt 2):13-21. PubMed ID: 6143743
[TBL] [Abstract][Full Text] [Related]
18. [Influence of clozapine on neuroleptigenic extrapyramidal motor disturbances (author's transl)].
Zander KJ; Rüther E
Arzneimittelforschung; 1978; 28(9):1495-6. PubMed ID: 38808
[TBL] [Abstract][Full Text] [Related]
19. Motoric neurological soft signs and psychopathological symptoms in schizophrenic psychoses.
Jahn T; Hubmann W; Karr M; Mohr F; Schlenker R; Heidenreich T; Cohen R; Schröder J
Psychiatry Res; 2006 Jun; 142(2-3):191-9. PubMed ID: 16650902
[TBL] [Abstract][Full Text] [Related]
20. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
Nasrallah HA; Brecher M; Paulsson B
Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
